Goldman Sachs
KPTI icon

Goldman Sachs’s Karyopharm Therapeutics KPTI Stock Holding History

Goldman Sachs’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.28M Buy
+947,579
New +$7.22M ﹤0.01% 3642
2025
Q4 		– Sell
-24,885
Closed -$163K – 6657
2025
Q3 		$163K Sell
24,885
-84,519
-77% -$455K ﹤0.01% 5990
2025
Q2 		$472K Buy
109,404
+23,994
+28% +$118K ﹤0.01% 5193
2025
Q1 		$319K Sell
85,410
-3,641
-4% -$31.1K ﹤0.01% 5419
2024
Q4 		$903K Sell
89,051
-63
-0.1% -$762 ﹤0.01% 4889
2024
Q3 		$1.11M Sell
89,114
-63,582
-42% -$790K ﹤0.01% 4564
2024
Q2 		$1.99M Buy
152,696
+52,145
+52% +$863K ﹤0.01% 3925
2024
Q1 		$2.28M Buy
100,551
+14,111
+16% +$247K ﹤0.01% 3779
2023
Q4 		$1.12M Sell
86,440
-41,230
-32% -$556K ﹤0.01% 4322
2023
Q3 		$2.57M Buy
127,670
+19,602
+18% +$440K ﹤0.01% 3569
2023
Q2 		$2.9M Buy
108,068
+10,125
+10% +$436K ﹤0.01% 3585
2023
Q1 		$5.71M Buy
97,943
+27,501
+39% +$1.36M ﹤0.01% 2934
2022
Q4 		$3.59M Sell
70,442
-19,903
-22% -$1.38M ﹤0.01% 3471
2022
Q3 		$7.4M Sell
90,345
-6,082
-6% -$454K ﹤0.01% 2789
2022
Q2 		$6.52M Buy
96,427
+36,500
+61% +$3.35M ﹤0.01% 2892
2022
Q1 		$6.63M Sell
59,927
-8,665
-13% -$1.08M ﹤0.01% 3082
2021
Q4 		$6.62M Buy
68,592
+2,900
+4% +$289K ﹤0.01% 3140
2021
Q3 		$5.74M Sell
65,692
-1,356
-2% -$141K ﹤0.01% 3241
2021
Q2 		$10.4M Sell
67,048
-13,750
-17% -$2M ﹤0.01% 2659
2021
Q1 		$12.8M Buy
80,798
+10,481
+15% +$2.21M ﹤0.01% 2339
2020
Q4 		$16.3M Buy
70,317
+12,672
+22% +$2.94M ﹤0.01% 2027
2020
Q3 		$12.6M Sell
57,645
-75,694
-57% -$18.5M ﹤0.01% 2113
2020
Q2 		$37.9M Buy
133,339
+69,389
+109% +$20.5M 0.01% 1185
2020
Q1 		$18.4M Buy
63,950
+26,880
+73% +$7.41M 0.01% 1573
2019
Q4 		$10.7M Sell
37,070
-1,338
-3% -$290K ﹤0.01% 2386
2019
Q3 		$5.54M Buy
38,408
+27,357
+248% +$3.71M ﹤0.01% 2782
2019
Q2 		$993K Buy
11,051
+147
+1% +$11.8K ﹤0.01% 4002
2019
Q1 		$955K Buy
10,904
+176
+2% +$19.5K ﹤0.01% 4080
2018
Q4 		$1.51M Sell
10,728
-7,864
-42% -$1.33M ﹤0.01% 3707
2018
Q3 		$4.75M Sell
18,592
-15,274
-45% -$4.22M ﹤0.01% 3021
2018
Q2 		$8.63M Buy
33,866
+26,430
+355% +$6.54M ﹤0.01% 2521
2018
Q1 		$1.5M Buy
7,436
+2,229
+43% +$444K ﹤0.01% 3784
2017
Q4 		$750K Sell
5,207
-176
-3% -$28.3K ﹤0.01% 4517
2017
Q3 		$887K Buy
5,383
+2,247
+72% +$322K ﹤0.01% 4678
2017
Q2 		$426K Sell
3,136
-2,179
-41% -$323K ﹤0.01% 5222
2017
Q1 		$1.02M Sell
5,315
-1,465
-22% -$235K ﹤0.01% 4353
2016
Q4 		$956K Buy
6,780
+3,546
+110% +$479K ﹤0.01% 4498
2016
Q3 		$472K Buy
3,234
+483
+18% +$58K ﹤0.01% 5096
2016
Q2 		$277K Buy
2,751
+2,035
+284% +$264K ﹤0.01% 5411
2016
Q1 		$96K Buy
+716
New +$79K ﹤0.01% 6091
2015
Q4 		– Sell
-301
Closed -$47K – 7261
2015
Q3 		$47K Sell
301
-4,091
-93% -$1.09M ﹤0.01% 6814
2015
Q2 		$1.79M Buy
4,392
+889
+25% +$384K ﹤0.01% 3946
2015
Q1 		$1.61M Buy
3,503
+589
+20% +$254K ﹤0.01% 4001
2014
Q4 		$1.64M Buy
2,914
+2,277
+357% +$1.29M ﹤0.01% 4056
2014
Q3 		$334K Sell
637
-62
-9% -$35K ﹤0.01% 5658
2014
Q2 		$488K Sell
699
-731
-51% -$340K ﹤0.01% 5345
2014
Q1 		$663K Buy
+1,430
New +$725K ﹤0.01% 5030

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Goldman Sachs's KPTI Position: Q1 2026 in Review

Goldman Sachs opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 947,579 shares worth $5.28M. The stake represents ﹤0.01% of the portfolio and ranks #3642 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in KPTI as recently as Q3 2025.

Goldman Sachs first reported a position in KPTI in Q1 2014 and has held it in 47 quarters since. The position peaked at $37.9M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Goldman Sachs held 947,579 shares of Karyopharm Therapeutics worth $5.28M as of Q1 2026.
  • Karyopharm Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3642 holding.
  • Goldman Sachs first reported a position in Karyopharm Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Goldman Sachs's Karyopharm Therapeutics position peaked at $37.9M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.